Cortexin

MK-801 model showed higher correlation with schizophrenia patient gene expression (r=0.40) than MAM model (r=0.15).; 11 of 28 co-expression modules were significantly associated with schizophrenia-related behavioral endophenotypes.; Brown module linked to hyperlocomotion was enriched in Wnt signaling; darkgrey module linked to social withdrawal was enriched in PI3K/Akt signaling.; Inhibiting these pathways specifically corrected corresponding behavioral anomalies in the MK-801 model.

Anxiety and depression are prevalent in a majority of rosacea patients.; Age and gender modulate the psychiatric burden associated with rosacea.; Inflammatory mediators, lipid metabolism, and neurotropic factors are implicated in the rosacea-psychiatric link.; Dermatologists should adopt interdisciplinary treatment plans to address psychological sequelae.

Cortexin improved concentration (p < 0.05) and executive function control (p < 0.05).; Auditory-verbal memory significantly improved (p = 0.002).; No adverse events were reported in the Cortexin group.; Cortexin is recommended as part of combined staged therapy for post-COVID cognitive impairment.

MoCA scores improved significantly from 25.1 to 28.4 after two courses of Cortexin.; Cognitive improvements were maintained at delayed testing (28.0 points).; Quality of life (SF-36) showed significant improvement after the fourth visit and persisted positively.; Cortexin was effective, safe, and well tolerated in young post-stroke patients.

Cerebrolysin probably results in little to no difference in all-cause death (RR 0.96, 95% CI 0.65 to 1.41; moderate-certainty).; Cerebrolysin probably results in little to no difference in total serious adverse events (RR 1.16, 95% CI 0.81 to 1.66; moderate-certainty).; Cerebrolysin may increase non-fatal serious adverse events (RR 2.39, 95% CI 1.10 to 5.23; moderate-certainty), especially with 30 mL for 10 days (RR 2.87, 95% CI 1.24 to 6.69).; No studies reported on poor functional outcome, quality of life, or early death.

Social cognition is examined as a separate cognitive function crucial for normal mental development.; The theory of mind and its neurobiological foundations are discussed.; Social competence deficits are reported in children with autism, specific language impairment, ADHD, and specific learning disorder.; Neurocognitive deficits in social cognition and possibilities for pharmacological correction are considered.

PCS is a complex, multifactorial condition that does not depend on the severity of the initial COVID-19 infection.; PCS significantly reduces quality of life and tends to have a protracted course.; The review covers epidemiology, pathogenesis, clinical presentation, and diagnosis of PCS.; Therapeutic approaches, including Cortexin, are discussed based on theoretical and clinical data.

High glucose (50 mM) caused a significant decrease in mean area under the curve (AUC) compared to normoglycemic conditions.; Cortexin co-treatment attenuated the high glucose-induced effect in a concentration-dependent manner.; At 40 μg/mL, Cortexin increased AUC from 0.18 to 0.66 (p=0.002 vs. high glucose alone).; Cortexin alone increased AUC in normoglycemic conditions in a concentration-dependent manner.

What is Cortexin?

**Mechanism of Action** Cortexin is a low-molecular-weight polypeptide complex extracted from bovine cerebral cortex. It is proposed to exert neuroprotective and nootropic effects through multiple mechanisms, including modulation of GABAergic and glutamatergic neurotransmission, reduction of oxidative stress, and enhan

How does Cortexin work?

Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.

What is the research status of Cortexin?

Cortexin is currently classified as clinical trials, with 202 research references on record. This is for research purposes only and is not medical advice.